Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada: Comparative efficacy and cost-effectiveness

Thrombosis and Haemostasis

Volumn 108, Issue 4, 2012, Pages 672-682

  Kansal, Anuraag R ^a   Sharma, Michael ^b   Bradley Kennedy, Carole ^c   Clemens, Andreas ^d   Monz, Brigitta U ^d   Peng, Siyang ^a   Roskell, Neil ^e   Sorensen, Sonja V ^a  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c BOEHRINGER INGELHEIM CANADA LTD   (Canada)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e RTI HEALTH SOLUTIONS   (United States)

Author keywords

Anticoagulation; Atrial fibrillation; Cost effectiveness; Dabigatran; RE LY; Rivaroxaban; ROCKET AF

Indexed keywords

DABIGATRAN ETEXILATE; RIVAROXABAN; WARFARIN;

ARTICLE; BLEEDING; CANADA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE COMPARISON; DRUG SAFETY; EMBOLISM; HEART ATRIUM FIBRILLATION; HUMAN; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK; SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; CANADA; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; EMBOLISM; HUMANS; MARKOV CHAINS; MODELS, ECONOMIC; MORPHOLINES; QUALITY-ADJUSTED LIFE YEARS; STROKE; THIOPHENES; TREATMENT OUTCOME; WARFARIN;

EID: 84867259621     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-06-0388     Document Type: Article

References (40)

1. Gladstone DJ, Bui E, Fang J, et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke 2009; 40: 235-240.
2. Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 2005; 36: 1115-1119.
3. Flaherty ML, Tao H, Haverbusch M, et al. Warfarin use leads to larger intracerebral hematomas. Neurology 2008; 71: 1084-1089.
4. Boehringer Ingelheim Canada Ltd. Pradax™ Dabigatran Etexilate capsules product monograph. Available at: http://www.boehringer-ingelheim.ca/en/Home/Human_Health/Our_Products/Product_Monographs/Pradax-pm.pdf. Accessed March 20, 2012.
5. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
6. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363: 1875-1876.
7. Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS Focused Up-date on the Management of Patients With Atrial Fibrillation (Update on Dabigatran) A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Heart Rhythm 2011; 8: e1-8.
8. National Institute for Health and Clinical Excellence (NICE). Atrial fibrillation -dabigatran etexilate (TA249). Final Guidance.; March 2012. Available at: http://www.nice.org.uk/ta249. Accessed March 20, 2012.
9. Skanes AC, Healey JS, Cairns JA, et al. Focused 2012 update of the canadian cardiovascular society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Canad J Cardiol 2012; 28: 125-136.
10. Bayer Inc. XARELTO™ Rivaroxaban tablet 10 mg, 15 mg and 20 mg anticoagulant product monograph. Available at: http://www.bayer.ca/files/XARELTO-PM-ENG-13FEB2012-145763.pdf. Accessed March 20, 2012.
11. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
12. Sorensen SV, Kansal AR, Connolly S, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost 2011; 105: 908-919.
13. Sorensen SV, Dewilde S, Singer DE, et al. Cost-effectiveness of warfarin: trial versus "real-world stroke prevention in atrial fibrillation. Am Heart J 2009; 157: 1064-1073.
14. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998; 13: 397-409.
15. Menon D, Stafinski T. Health technology assessment in Canada: 20 years strong? Value Health 2009; 12 (Suppl 2): S14-19.
16. Fleming TR, Emerson SS. Evaluating rivaroxaban for nonvalvular atrial fibrillation--regulatory considerations. N Engl J Med 2011; 365: 1557-1559.
17. FDA Advisory Committee Briefing Document - Rivaroxaban. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeeting Materials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM270796.pdf. Accessed January 26, 2012.
18. Sullivan PW, Arant TW, Ellis SL, et al. The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US. Pharmacoeconomics 2006; 24: 1021-1033.
19. Tengs TO, Lin TH. A meta-analysis of quality-of-life estimates for stroke. Pharmacoeconomics 2003; 21: 191-200.
20. Ontario Drug Benefit Program. Drugs Funded by Ontario Drug Benefit (ODB) Program: E-Formulary. 2011; Available at: http://www.health.gov.on.ca/english/providers/program/drugs/odbf_eformulary.html. Accessed March 11, 2011.
21. Bayer Health Care. Xarelto 20mg price document. January 17, 2012.
22. Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada [3rd Edition]. Ottawa; 2006
23. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997; 50: 683-691.
24. Song F, Altman DG, Glenny AM, et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published metaanalyses. Br Med J 2003; 326: 472.
25. Canadian Agency for Drugs and Technology in Health. Indirect Evidence: Indirect Treatment Comparisons in Meta-Analysis, March, 2009. Available at: http://www.cadth.ca. Accessed March 21, 2012.
26. FDA Advisory Committee Briefing Document - Dabigatran. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM247244.pdf. Accessed January 17, 2012.
27. Johnson & Johnson Pharmaceutical Research & Development Advisory Committee Briefing Document Rivaroxaban for the Prevention of Stroke and Non-Central Nervous System (CNS) Systemic Embolism in Patients with Atrial Fibrillation. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM270797.pdf. Accessed January 26, 2012.
28. Jones M, McEwan P, Morgan CL, et al. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart 2005; 91: 472-477.
29. Canadian Agency for Drugs and Technology in Health. New Oral Anticoagulants for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation. April 9, 2012. Available at: http://www.cadth.ca/media/pdf/NOAC_Therapeutic_Review_final_report.pdf. Accessed April 20, 2012.
30. Lip G, Larsen T, Skjøth F, et al. Indirect Comparisons of New Oral Anticoagulant Drugs for Efficacy and Safety When Used for Stroke Prevention in Atrial Fibrillation. J Am Coll Cardiol 2012; Epub ahead of print.
31. Mantha S, Ansell J. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost 2012; 108: 476-484.
32. Testa L, Angnifili M, Latini R, et al. Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation. QJM 2012; Epub ahead of print.
33. Kansal AR, Sorensen SV, Gani R, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart 2012; 98: 573-578.
34. Canadian Agency for Drugs and Technology in Health. CEDAC final recommendation: Dabigatran etexilate New indication: Prevention of stroke and systemic embolism in patients with atrial fibrillation, June 22, 2011. Available at: http://www.cadth.ca. Accessed January 16, 2012.
35. Kamel H, Johnston SC, Easton JD, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke 2012; 43: 881-883.
36. Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011; 154: 1-11.
37. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 2011; 123: 2562-2570.
38. Pink J, Lane S, Pirmohamed M, et al. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefitharm and economic analyses. Br Med J 2011; 343: d6333.
39. Pengo V, Crippa L, Falanga A, et al. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost 2011; 106: 868-876.
40. Mahaffey KW, Fox KA. Rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. American Heart Association; 2010. Available at: https://www.dtmi.duke.edu/website-administration/files/ROCKET-AF-LBCTFINAL.ppt/view?searchterm=ROCKET. Accessed April 27, 2012.